Pixium Vision switched to developing the sub-retinal implant Prima after its initial device, Iris II, was found to have a shorter lifespan than the group had hoped. Now data from the first feasibility trial of Prima are in, and while these are positive they have not allowed Pixium’s stock to rebound from the fall caused by the switch of devices. Prima consists of an photovoltaic chip containing 378 electrodes that is implanted under the retina. It detects light from images shot by a camera integrated into augmented reality glasses, improving vision in patients with age-related macular degeneration or retinitis pigmentosa. One year after the device was implanted, all five patients in the Paris-based Prima-FS trial had light perception in the central retinal area – none had had central visual activity at enrolment – meeting the study’s primary endpoint. Most of the patients could identify letters, and some sequences of letters. Crucially, there were no serious adverse events – a safety signal seen with the Orion system developed by Pixium’s main rival, Second Sight Medical Products, hurt that company back in April. Pixium’s feasibility trial will continue out to three years, and Prima is also in a similar five-patient US feasibility study.
|Pixium vs Second Sight|
|Annual sales ($m)|
|Second Sight||Argus II and Orion||7||7||7||11||18||42||98||+56%|